Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $765,400.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.27, for a total transaction of $765,400.00. Following the completion of the sale, the insider owned 73,969 shares of the company’s stock, valued at approximately $2,830,793.63. The trade was a 21.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Anne Lesage also recently made the following trade(s):

• On Thursday, September 10th, Anne Lesage sold 30,000 shares of Pharvaris stock. The stock was sold at an average price of $38.30, for a total value of $1,149,000.00.
• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The shares were sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total value of $245,244.85.
• On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total value of $371,742.00.

Pharvaris Price Performance

Shares of PHVS stock opened at $33.07 on Thursday. The business’s fifty day moving average price is $35.36 and its 200 day moving average price is $31.93. The firm has a market capitalization of $2.16 billion, a PE ratio of -10.84 and a beta of -2.33. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities research analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Rosenblatt Securities set a $60.00 price objective on shares of Pharvaris in a research note on Wednesday, September 9th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research report on Tuesday, September 8th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Guggenheim lifted their price target on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Citizens Jmp boosted their price target on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

Institutional Investors Weigh In On Pharvaris

A number of large investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. raised its position in Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after acquiring an additional 281,829 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Pharvaris in the second quarter valued at about $26,677,000. Seven Fleet Capital Management LP increased its stake in shares of Pharvaris by 472.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after purchasing an additional 261,355 shares in the last quarter. DV Trading LLC purchased a new stake in Pharvaris in the 1st quarter valued at approximately $4,067,000. Finally, Moore Capital Management LP purchased a new stake in Pharvaris in the 2nd quarter valued at approximately $1,522,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.